Some design issues in trials of microbicides for the prevention of HIV infection.
about
Notes on the frequency of routinely collected and self-reported behavioral data in HIV prevention trials.Some design issues in phase 2B vs phase 3 prevention trials for testing efficacy of products or conceptsIncreasing the Efficiency of Prevention Trials by Incorporating Baseline CovariatesImplications of HIV PrEP trials results.Effectiveness of female controlled barrier methods in preventing sexually transmitted infections and HIV: current evidence and future research directions.Fishermen as a Suitable Population for HIV Intervention TrialsHPTN 035 phase II/IIb randomised safety and effectiveness study of the vaginal microbicides BufferGel and 0.5% PRO 2000 for the prevention of sexually transmitted infections in womenSafety and effectiveness of BufferGel and 0.5% PRO2000 gel for the prevention of HIV infection in womenAntiretroviral-based HIV prevention strategies for women.Randomized phase II trial of selenomethionine as a modulator of efficacy and toxicity of chemoradiation in squamous cell carcinoma of the head and neckBeating the placebo in HIV prevention efficacy trials: the role of the minimal efficacy bound.Appropriateness of hydroxyethylcellulose gel as a placebo control in vaginal microbicide trials: a comparison of the two control arms of HPTN 035.Partially hidden Markov model for time-varying principal stratification in HIV prevention trials.Randomized phase II designs.Pharmaceutical development of microbicide drug products.Meta-analyses and adaptive group sequential designs in the clinical development process.A randomised phase IIb trial to assess the efficacy of ReCharge ice cream in preventing chemotherapy-induced diarrhoea.Recommended changes to oncology clinical trial design: revolution or evolution?An adaptive design to bridge the gap between Phase 2b/3 microbicide effectiveness trials and evidence required for licensure.HIV prevention trial design in an era of effective pre-exposure prophylaxis.Challenges in microbicide trial design and implementation.Basis and Statistical Design of the Passive HIV-1 Antibody Mediated Prevention (AMP) Test-of-Concept Efficacy Trials.When to stop treatment arms in a clinical trial assessing time to event with more than two arms against a common control.
P2860
Q33722251-252A2F80-248F-4CD3-BAEA-3E24686ABC13Q34090592-9AE29584-0E21-4A6C-BC42-1D8AE3223A27Q34383812-A29919A1-BF58-44C5-8923-096CEAF40B9BQ34460987-A58B68F1-1FDD-4012-A830-F14D1FC0D37BQ34558034-9FA51451-B7F9-49F3-B104-071DA27FD7EEQ34730059-9A8DED08-36DC-4A66-97BF-5F975CB37D8EQ34782269-4459D9FD-53AF-4C02-813F-1869163C2235Q34874237-20794CDA-30C6-41DC-BE17-2F8661C03D90Q35237188-12E0CC9E-B025-466B-9B00-046ADB05A12FQ36143844-A5C8F166-7FAB-4CF7-93E3-7B0221254111Q36487437-000522D6-972D-41A1-89FD-74D8B968C2BEQ36763200-C1A07213-D5FC-4C25-B37D-31B1B985DF3FQ36829482-6D2DAE39-39F8-4E27-8FFA-824D0147F088Q37173942-EEBB31E6-994E-4F8B-8A69-5659D860C090Q37657468-26D7785E-3AEE-4C40-BDD1-02A9488CC342Q38473067-2ACD84D1-2853-4B72-953D-3C0E2DB6811BQ40895870-CDBB77FC-81AB-48A5-919E-7CFAEE2FC984Q43140987-C0E6321A-9637-4CE1-8575-9146ED342FA9Q44016003-FC81B1FF-E991-489B-81C4-F0220E345A89Q45961960-46256E1A-5960-42A3-B324-B76263AB0E0FQ46219584-9DC5B648-6216-491D-8025-494AF49ACC99Q46296261-C9CCD1DC-5015-44B6-856E-56F0A051586EQ46556858-16E220C4-CD40-42F5-9260-81DD44A6D2BD
P2860
Some design issues in trials of microbicides for the prevention of HIV infection.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
2004年學術文章
@zh
2004年學術文章
@zh-hant
name
Some design issues in trials of microbicides for the prevention of HIV infection.
@en
Some design issues in trials of microbicides for the prevention of HIV infection.
@nl
type
label
Some design issues in trials of microbicides for the prevention of HIV infection.
@en
Some design issues in trials of microbicides for the prevention of HIV infection.
@nl
prefLabel
Some design issues in trials of microbicides for the prevention of HIV infection.
@en
Some design issues in trials of microbicides for the prevention of HIV infection.
@nl
P356
P1476
Some design issues in trials of microbicides for the prevention of HIV infection.
@en
P2093
Barbra A Richardson
Thomas R Fleming
P304
P356
10.1086/422603
P407
P577
2004-07-20T00:00:00Z